Immunocore Holdings plc (IMCR)
$29.39+1.03%Close
SELLBEAR · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.5B
- Beta
- 0.82
- P/E (TTM)
- -163.89
- Short % float
- 15.70%
- Days to cover
- 20.7
- SI change
- +1.7%
- 1W
- -1.08%
- 1M
- -12.48%
- vs SPY 1W
- -2.24%
- vs SPY 1M
- -15.47%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$4.2BCRISISQ -6$13.78+4.41%
- HRMYSELLHarmony Biosciences Holdings, Inc.$2.3BBEARQ 1$39.92+1.72%
- CLDXSELLCelldex Therapeutics, Inc.$2.2BCRISISQ 5$32.59+2.01%
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 21$29.83+0.50%
- BHVNSELLBiohaven Ltd.$2.0BCRISISQ 17$12.97+1.26%
- XERSBUYXeris Biopharma Holdings, Inc.$1.7BBULLQ -1$10.13+2.85%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.95+1.01%
- MNKDSELLMannKind Corporation$1.2BCRISISQ 4$3.82-3.80%
- JANXBUYJanux Therapeutics, Inc.$1.0BRECOVERYQ 12$16.54-0.59%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 11
- VALUE
- 1
- GROWTH
- 46
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-1.4%
REV YoY-
ROE-2.3%
EPS YoY-
ROA-0.8%
GROSS99
OP-4
NET-2
[VALUATION]
P/E TTM-163.89
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B3.59
P/FCF-
EV/EBITDA89.56
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E103.61
ALTMAN Z-
CURR RATIO4.47
ND/EBITDA-
BETA0.82
Company news
FAQ
- What is LOPJLB’s current signal on IMCR?
- LOPJLB’s latest quantitative signal on Immunocore Holdings plc (IMCR) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is IMCR in?
- Immunocore Holdings plc (IMCR) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Immunocore Holdings plc (IMCR) do?
- Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treat…